Evidence map›Paper›PMID 34264975›Full record

ArticlePloS one2021

Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy.

Hong Zhang, Christopher Doucette, Hongmei Yang, Sanjukta Bandyopadhyay, Craig E Grossman, Edward M Messing, Yuhchyau Chen

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hong ZhangDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, United States of America.ORCID 0000-0003-3631-9163
Christopher DoucetteDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, United States of America.
Hongmei YangDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, United States of America.
Sanjukta BandyopadhyayDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, United States of America.
Craig E GrossmanDepartment of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, United States of America.
Edward M MessingDepartment of Urology, University of Rochester Medical Center, Rochester, NY, United States of America.
Yuhchyau ChenDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntermediate risk prostate cancer represents a largely heterogeneous group with diverse disease extent. We sought to establish rates of adverse pathological features important for radiation planning by analyzing surgical specimens from men with intermediate risk prostate cancer who underwent immediate radical prostatectomy, and to define clinical pathologic features that may predict adverse outcomes. MATERIALS AND

methodsA total of 1552 men diagnosed with intermediate risk prostate cancer who underwent immediate radical prostatectomy between 1/1/2005 and 12/31/2015 were reviewed. Inclusion criteria included available preoperative PSA level, pathology reports of transrectal ultrasound-guided prostate biopsy, and radical prostatectomy. Incidences of various pathological adverse features were evaluated. Patient characteristics and clinical disease features were analyzed for their predictive values.

resultsFifty percent of men with high risk features (defined as PSA >10 but <20 or biopsy primary Gleason pattern of 4) had pathological upstage to T3 or higher disease. The incidence of upgrade to Gleason score of 8 or higher and the incidence of lymph node positive disease was low. Biopsy primary Gleason pattern of 4, and PSA greater than 10 but less than 20, affected adverse pathology in addition to age and percent positive biopsy cores. Older age and increased percentage of positive cores were significant risk factors of adverse pathology.

conclusionOur findings underscore the importance of comprehensive staging beyond PSA level, prostate biopsy, and CT/bone scan for men with intermediate risk prostate cancer proceeding with radiation in the era of highly conformal treatment.

Indexed as

Neoplasm GradingProstatectomyProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm StagingProstate-Specific AntigenRetrospective StudiesRisk FactorsProstate-Specific Antigen

Identifiers

PMID34264975
PMCPMC8281993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.